Vertex Pharmaceuticals (NASDAQ:VRTX) Issues Quarterly Earnings Results

Vertex Pharmaceuticals (NASDAQ:VRTX) released its quarterly earnings data on Monday. The pharmaceutical company reported $4.06 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.29 by ($0.23), RTT News reports. Vertex Pharmaceuticals had a negative return on equity of 2.02% and a negative net margin of 4.86%. The business had revenue of $2.77 billion during the quarter, compared to analysts’ expectations of $2.85 billion. During the same quarter in the previous year, the company posted $4.76 EPS. The company’s revenue was up 2.6% compared to the same quarter last year. Vertex Pharmaceuticals updated its FY 2025 guidance to EPS.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $450.03 on Wednesday. The company’s fifty day moving average price is $491.94 and its two-hundred day moving average price is $466.80. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market capitalization of $115.69 billion, a P/E ratio of -204.56, a P/E/G ratio of 2.11 and a beta of 0.51. Vertex Pharmaceuticals has a 12 month low of $377.85 and a 12 month high of $519.88.

Insider Transactions at Vertex Pharmaceuticals

In related news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction on Monday, March 10th. The shares were sold at an average price of $500.00, for a total value of $1,615,500.00. Following the completion of the sale, the executive vice president now owns 26,512 shares in the company, valued at approximately $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ourania Tatsis sold 310 shares of the stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $459.83, for a total transaction of $142,547.30. Following the transaction, the executive vice president now owns 64,021 shares in the company, valued at $29,438,776.43. This trade represents a 0.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 4,315 shares of company stock valued at $2,121,012. 0.20% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Vertex Pharmaceuticals stock. Brighton Jones LLC boosted its stake in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 15.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,427 shares of the pharmaceutical company’s stock after purchasing an additional 579 shares during the quarter. Brighton Jones LLC’s holdings in Vertex Pharmaceuticals were worth $1,783,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 90.96% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on VRTX. Wells Fargo & Company downgraded Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and set a $460.00 target price on the stock. in a research report on Thursday, January 30th. Leerink Partners reiterated a “market perform” rating and set a $503.00 target price (down previously from $550.00) on shares of Vertex Pharmaceuticals in a report on Tuesday. Barclays lifted their price objective on Vertex Pharmaceuticals from $435.00 to $467.00 and gave the stock an “equal weight” rating in a research report on Tuesday, February 11th. Canaccord Genuity Group upgraded shares of Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and upped their target price for the company from $408.00 to $424.00 in a report on Tuesday, February 11th. Finally, Royal Bank of Canada lifted their price target on shares of Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a “sector perform” rating in a report on Tuesday. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Vertex Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $515.04.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.